Loading stock…

Melexis NV (MELE) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

MELEMelexis

Revenue FY25$983M

GROWTH RATING↗

AVERAGE44 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+8%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+4%5

EPS growth, FY27E+26%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 3%/yr over the last 3 years and is set to grow 7%/yr from here.

Earnings are set to grow faster than sales (EPS about 19%/yr vs revenue 7%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 44% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little behind the market.4/10

Over five years revenue is set to grow 8%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's speeding up. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MELEMelexis

Total return Current61.3%

Price return Current16.2%

MOMENTUM RATING↗

AVERAGE35 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-6%5

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high80%5

1-year return+6%5

3-year return-7%2

5-year return-14%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+1%) and so far this year (+22%).

WATCH

It's up 6% over the past year, but 20% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.2% over three years and -14% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Melexis NV. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MELEMelexis

Revenue FY25$983M

GROWTH RATING↗

AVERAGE44 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+8%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+4%5

EPS growth, FY27E+26%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 3%/yr over the last 3 years and is set to grow 7%/yr from here.

Earnings are set to grow faster than sales (EPS about 19%/yr vs revenue 7%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 44% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little behind the market.4/10

Over five years revenue is set to grow 8%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's speeding up. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MELEMelexis

Total return Current61.3%

Price return Current16.2%

MOMENTUM RATING↗

AVERAGE35 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-6%5

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high80%5

1-year return+6%5

3-year return-7%2

5-year return-14%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+1%) and so far this year (+22%).

WATCH

It's up 6% over the past year, but 20% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.2% over three years and -14% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Melexis NV. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Melexis NV

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Melexis NV. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Melexis NV. Get the full investment case.

Premium